Publication details
Betablokátory a kardiovaskulární onemocnění - kontroverze 2023
| Title in English | Betablockers and CV disease - controversy 2023 |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| MU Faculty or unit | |
| Citation | |
| web | https://klinickafarmakologie.cz/artkey/far-202401-0001_betablokatory_a_kardiovaskularni_onemocneni_-_kontroverze_2023.php |
| Doi | https://doi.org/10.36290/far.2024.001 |
| Keywords | beta blockers; heart failure; hypertension; arrhythmia; CHD; perioperative care |
| Description | Beta-blockers are used for a wide range of cardiovascular diseases (CVD) - from arterial hypertension to heart failure. Recently, however, a number of analyzes and information have appeared that question the role of beta-blockers in some indications. We provide an overview of the controversies that have arisen around beta-blockers in the treatment of heart failure, hypertension, arrhythmias, in the secondary prevention of ischemic heart disease, and in perioperative administration to patients during non-cardiac operations. |